In Brief: FDA pharmacoeconomics conference
Executive Summary
FDA pharmacoeconomics conference: "Comparing Treatments: Safety, Effectiveness, and Cost-Effectiveness" will explore "methodological and regulatory principles that should be used to guide research design, review and communications when direct comparisons are made between active drug/biological treatments." Topics for the March 23-24 meeting include: "What type of information is needed in the managed care/payor communities?" and "How is the pharmaceutical industry responding to these new demands?" The conference will be held at NIH's Masur Auditorium. To register and get a preliminary program call (301) 594-6812 or fax (301) 594-6759...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth